$SGMOQ Cashflow Statement | Understand Stock

$SGMOQ

$0.16 -$0.01 (3.13%) Close

$SGMOQ Overview Financial Statements SEC Filings Executives News Red Flags Capital Raising Ownership Insider Transactions Congressional Trades

Financial Statements

Income Statement Balance Sheet Cashflow Statement

Consolidated statements of cash flows

In millions of USD, except per-share amounts

	FY2025 12 months to Dec 31, 2025	FY2024 12 months to Dec 31, 2024	FY2023 12 months to Dec 31, 2023	FY2022 12 months to Dec 31, 2022	FY2021 12 months to Dec 31, 2021
Operating Activities:
Net loss
Adjustments to reconcile net loss to net cash used in operating activities:
Impairment of long-lived assets
Depreciation and amortization
Accretion of discount and impairment on marketable securities
Amortization of operating lease right-of-use assets
Stock-based compensation
Gain on free shares
Gain on sale of assets classified as held for sale
Other
Adjustment of CIRM award liability related to termination of the grant
Net loss on lease termination
Impairment of goodwill and indefinite-lived intangible assets
Deferred income tax benefit

Net changes in operating assets and liabilities:
Interest receivable
Accounts receivable
Refundable research income tax credits
Prepaid expenses and other assets
Accounts payable and other accrued liabilities
Accrued compensation and employee benefits
Deferred revenues
Long-term portion of lease liabilities
Lease liabilities
Other non-current liabilities

Net cash used in operating activities
Investing Activities:
Purchases of marketable securities
Maturities of marketable securities
Sales of marketable securities
Proceeds from sale of marketable securities
Proceeds from sale of assets classified as held for sale
Purchases of property and equipment
Purchase of additional Sangamo France shares
Net cash (used in) provided by investing activities
Financing Activities:
Proceeds from at-the-market offering, net of offering expenses
Proceeds from issuance of common stock, net of offering expenses
At-The-Market Offering
Public Offering
Biogen Collaboration Agreement
Employee Stock
Total proceeds from issuance of common stock, net of offering expenses

Taxes paid related to net share settlement of equity awards
Proceeds from exercise of stock options
Proceeds from issuance of common stock under employee stock purchase plan
Net cash provided by financing activities
Effect of exchange rate changes on cash and cash equivalents and restricted cash
Net decrease in cash, cash equivalents and restricted cash
Cash, cash equivalents and restricted cash, beginning of period
Cash, cash equivalents and restricted cash, end of period
Supplemental cash flow disclosures:
Property and equipment included in unpaid liabilities
Tenant improvement allowance included in contra-lease liability
Buy-out of non-controlling interest
Right-of-use assets obtained in exchange for lease obligations

Comments